|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.006400 USD | -36.63% |
|
-.--% | - |
| 03-13 | Beroni Group Limited Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 12/09/25 | Beroni Group Limited Reports Earnings Results for the Half Year Ended June 30, 2025 | CI |
| Capitalization | 336K 240K 207K 189K 179K 330K 23.21M 2.24M 877K 10.96M 902K 883K 38.16M | P/E ratio 2024 |
-2.72x | P/E ratio 2025 | -0.07x |
|---|---|---|---|---|---|
| Enterprise value | 1.71M 1.22M 1.05M 963K 910K 1.68M 118M 11.41M 4.47M 55.77M 4.59M 4.49M 194M | EV / Sales 2024 |
109x | EV / Sales 2025 | 2.68x |
| Free-Float |
21.57% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -36.63% |
| 1 year | 0.01 | 0.01 | |
| 3 years | 0.01 | 9.88 | |
| 5 years | 0.01 | 17.2 | |
| 10 years | 0.01 | 17.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Bo Qing Zhang
CEO | Chief Executive Officer | 57 | 17/06/2016 |
Yap Ting Wong
DFI | Director of Finance/CFO | 64 | 02/07/2018 |
Chen Chik Ong
SEC | Corporate Secretary | 47 | 01/03/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Chen Chik Ong
BRD | Director/Board Member | 47 | 01/03/2021 |
Richard Buchta
BRD | Director/Board Member | 68 | 01/07/2020 |
Yap Ting Wong
BRD | Director/Board Member | 64 | 30/09/2016 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -36.63% | -.--% | -36.63% | -99.93% | 218K | ||
| +0.81% | +0.31% | +36.39% | +130.32% | 909B | ||
| -0.47% | -0.48% | +49.24% | +44.31% | 552B | ||
| -0.26% | +1.82% | +14.85% | +46.30% | 375B | ||
| -0.15% | +2.53% | +24.56% | +13.82% | 332B | ||
| -0.54% | +0.87% | +32.10% | +15.15% | 291B | ||
| +0.17% | +1.75% | +26.62% | +30.12% | 287B | ||
| -0.23% | -0.40% | +44.93% | -2.16% | 279B | ||
| -0.99% | +0.10% | -37.30% | -51.47% | 199B | ||
| -0.01% | -1.45% | +20.57% | +48.41% | 179B | ||
| Average | -3.88% | +0.67% | +17.53% | +17.49% | 340.31B | |
| Weighted average by Cap. | -0.07% | +1.03% | +29.32% | +51.63% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 317K 227K 195K 179K 169K 312K 21.91M 2.12M 828K 10.34M 851K 833K 36.03M | 638K 457K 393K 360K 340K 628K 44.15M 4.27M 1.67M 20.84M 1.72M 1.68M 72.59M |
| Net income | -10.61M -7.6M -6.53M -5.98M -5.65M -10.44M -734M -70.88M -27.74M -346M -28.5M -27.9M -1.21B | -4.22M -3.02M -2.6M -2.38M -2.25M -4.16M -292M -28.22M -11.04M -138M -11.35M -11.11M -480M |
| Net Debt | -254K -182K -157K -143K -136K -250K -17.6M -1.7M -665K -8.31M -684K -669K -28.94M | 1.37M 983K 845K 774K 731K 1.35M 94.93M 9.17M 3.59M 44.81M 3.69M 3.61M 156M |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Equities
- BNIG.F Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















